Anteris Technologies Stock Drops 5.4%

Shares of the medical device company fell amid broader market declines.

Apr. 16, 2026 at 5:07pm

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up image of the complex mechanical components and gears of a medical device, conveying a sense of the intricate engineering and manufacturing behind Anteris Technologies' products.The inner workings of Anteris Technologies' innovative medical devices reflect the company's engineering expertise and commitment to advancing heart disease treatments.Eagan Today

Shares of Anteris Technologies Global (NASDAQ:AVR) fell 5.4% during trading on Thursday, closing at $5.95. The stock traded as low as $5.94 on volume of 78,154 shares, down from the average daily volume of 1,192,938 shares.

Why it matters

Anteris Technologies is a medical device company focused on heart disease treatments. The stock's decline reflects broader volatility in the market, as investors weigh economic conditions and the outlook for the healthcare sector.

The details

Several Wall Street analysts have issued reports on Anteris Technologies in recent months. Cantor Fitzgerald reiterated an "overweight" rating and $15 price target on the stock, while Weiss Ratings maintained a "sell (e+)" rating. Wells Fargo initiated coverage with an "overweight" rating and $16 price target.

  • Anteris Technologies stock closed at $5.95 on April 16, 2026.
  • The stock traded as low as $5.94 during the trading session.

The players

Anteris Technologies Global

A medical device company focused on developing treatments for heart diseases.

Cantor Fitzgerald

A Wall Street investment bank that covers Anteris Technologies and has an "overweight" rating on the stock.

Weiss Ratings

A financial research firm that has a "sell (e+)" rating on Anteris Technologies stock.

Wells Fargo

A major U.S. bank that recently initiated coverage of Anteris Technologies with an "overweight" rating and $16 price target.

Got photos? Submit your photos here. ›

The takeaway

The decline in Anteris Technologies' stock price reflects broader market volatility, as investors assess the outlook for the healthcare sector. However, the company maintains a "Moderate Buy" rating from analysts, who see potential upside in the stock based on its medical device pipeline and market positioning.